Core Insights - DexCom, Inc. reported weaker-than-expected earnings for Q4, with earnings of $0.45 per share, missing the analyst consensus estimate of $0.50 per share, while quarterly sales of $1.140 billion exceeded the consensus estimate of $1.104 billion [1] - The company plans to expand its US commercial sales force and has launched two major products, Dexcom One+ and Stelo, while also submitting the G7 15-day product to the FDA [2] - DexCom reaffirmed its FY25 guidance, projecting revenue of $4.60 billion, an adjusted gross profit margin of around 64%-65%, and an adjusted operating margin of 21% [2] Stock Performance - DexCom shares increased by 0.3%, closing at $84.09 following the earnings announcement [3] - Analysts have adjusted their price targets for DexCom, with Morgan Stanley maintaining an Equal-Weight rating and raising the target from $75 to $82, while Canaccord Genuity maintained a Buy rating and increased the target from $99 to $103 [4]

Core Insights - DexCom, Inc. reported fourth-quarter 2024 adjusted earnings per share (EPS) of 45 cents, missing the Zacks Consensus Estimate of 50 cents by 10% and down from 50 cents in the prior-year quarter [1] - Total revenues grew 7.6% year over year to $1.11 billion, driven by strong new patient performance and expanded availability of its G7 and DexCom ONE+ product platforms [2] - The company expects 2025 revenues to be $4.6 billion, implying 14% year-over-year growth, in line with the Zacks Consensus Estimate [10] Revenue Performance - Total revenues increased by 7.6% (8% on an organic basis) to $1.11 billion year over year [2] - Sensor and other revenues, which account for 96% of total revenues, rose 13% year over year to $1.07 billion, while hardware revenues decreased by 49% year over year to $45 million [5] - U.S. revenues (72% of total revenues) increased 4.4% year over year to $802.8 million, and international revenues (28%) improved 17.1% (19% on an organic basis) year over year to $310.7 million [6] Margin Analysis - Adjusted gross profit totaled $661.2 million, down 0.4% from the prior-year quarter, with an adjusted gross margin of 59.4%, down 480 basis points year over year [7] - Adjusted operating margin was 18.8%, down 460 basis points year over year, with total adjusted operating expenses of $209.5 million, down 13.7% from the prior-year period [8] Financial Position - The company exited the fourth quarter with $2.58 billion in cash, cash equivalents, and marketable securities, compared to $2.49 billion in the third quarter [9] - Total assets amounted to $6.48 billion, up sequentially from $6.35 billion [9] Strategic Initiatives - DexCom's active customer base reached over 2.8 million users worldwide, up 25% from the 2023 level, driven by strategic initiatives including an expanded sales force and new product launches [12] - The company added more than 50,000 new U.S. prescribers, enhancing access to its CGM technology and driving record new patient starts in the fourth quarter [13] - Stelo has contributed significantly to growth, with over 140,000 users, particularly among type 2 diabetes and prediabetes populations [14] Market Expansion - International revenues are driven by expansion in markets such as France and New Zealand, with broader reimbursement coverage achieved [15] - DexCom is focusing on increasing basal insulin coverage across other markets, with early wins in Germany, Canada, Australia, and a growing presence in Japan [15] Future Outlook - The company expects adjusted gross margin to be 64-65% and adjusted operating margin to be approximately 21% for 2025 [11] - Key plans include the rollout of a 15-day wear G7 system, improved manufacturing efficiencies, and further penetration into the non-insulin diabetes market [16] - Reimbursement expansion is crucial, with coverage extending beyond insulin users, potentially granting access to over 5 million people with type 2 diabetes not on insulin [17]

Financial Data and Key Metrics Changes - The company reported fourth quarter organic revenue growth of 8% compared to Q4 2023, bringing full-year organic revenue growth to 12% [10][29] - Worldwide revenue for Q4 2024 was $1.11 billion, up from $1.03 billion in Q4 2023, representing an 8% increase [29] - US revenue totaled $803 million for Q4 2024, compared to $769 million in Q4 2023, reflecting a 4% increase [30] - International revenue grew 17% to $311 million in Q4, with international organic revenue growth at 19% [32] - Gross profit for Q4 was $661.2 million, or 59.4% of revenue, down from 64.2% in Q4 2023, impacted by a $21 million non-cash charge [34] - Operating income was $209.5 million, or 18.8% of revenue, compared to $242.7 million, or 23.5% of revenue in Q4 2023 [36] - Net income for Q4 was $177.8 million, or $0.45 per share, with cash and cash equivalents at approximately $2.6 billion [37] Business Line Data and Key Metrics Changes - The company ended 2024 with over 2.8 million customers globally on its G series and D series products, a 25% increase from 2023 [12] - The US prescriber base grew by more than 50,000 over the past year, contributing to record new customer starts [13][15] - The DME channel share remained stable during Q4, with expectations for improvement in 2025 [31] Market Data and Key Metrics Changes - The company achieved significant reimbursement wins, with two of the three largest PBMs covering CGM for anyone with diabetes as of January 2025 [19] - By the end of 2025, the company expects coverage for over five million people with type 2 diabetes who are not on insulin in the US [19] - Internationally, the company secured basal coverage for its One Plus system in France and expanded coverage in New Zealand [25][33] Company Strategy and Development Direction - The company is focused on broadening its commercial reach, launching new products, and advancing CGM reimbursement globally [11] - The launch of the over-the-counter product, Stella, aims to empower more individuals to take control of their health, with over 140,000 users in the first four months [21][23] - The company is leveraging generative AI technology to enhance the Stella platform and improve customer engagement [22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in entering 2025 with a stronger position to capitalize on growth opportunities [11] - The company anticipates total revenue of $4.6 billion in 2025, representing a 14% growth, with expectations for improved gross margins [38][39] - Management highlighted the importance of navigating the evolving coverage landscape and the growing economic argument for incorporating CGM earlier into care plans [16][18] Other Important Information - The company is actively pursuing coverage for the remaining 20 million type 2 non-insulin users in the US [20] - The FDA review for the fifteen-day G7 system is nearing completion, with expectations for a second-half launch [80] - The company is developing the G8 platform, which will be smaller and more capable, with multi-analyte capabilities [88][90] Q&A Session Summary Question: Status of Salesforce and DME issues - Management reported significant progress in addressing Salesforce productivity and DME channel issues, with improved metrics and record new starts [47][49] Question: Volume versus revenue gap in the US - Management indicated that the gap between volume and revenue is expected to converge throughout 2025, with improvements anticipated as rebate dynamics stabilize [55][56] Question: Cadence of growth through the year - Management expects a stable cadence of improvement throughout 2025, with a typical seasonal decline in Q1 but overall growth in the second half of the year [62][66] Question: Type 2 coverage impact on revenue - Management confirmed that the unit economics remain similar across disease states, with expectations for strong utilization and retention rates among newly covered type 2 patients [72][76] Question: G7 fifteen-day sensor approval process - Management expressed confidence in receiving FDA approval soon, with plans for a second-half launch and integration with pump partners [80][81] Question: Expectations for record new patient numbers in 2025 - Management anticipates a record year for new patients, driven by continued penetration in insulin-intensive segments and new type 2 coverage [104][110] Question: Assumptions behind 2025 growth guidance - Management provided insights into the conservative assumptions behind the 14% growth guidance, emphasizing the importance of stable DME share and the potential impact of new product launches [121][126]

Core Insights - DexCom reported mixed earnings for Q4 2024, with revenue growth of 8% to $1.114 billion, slightly exceeding analyst expectations, while Non-GAAP EPS fell to $0.45, below the forecast of $0.50 [2][3][6] Financial Performance - Revenue for Q4 2024 reached $1.114 billion, an 8% increase from $1.035 billion in Q4 2023, surpassing the estimate of $1.112 billion [3][6] - Non-GAAP EPS was $0.45, a 10% decline year-over-year from $0.50 in Q4 2023, falling short of the expected $0.50 [3][6] - Non-GAAP operating income decreased by 13.7% to $209.5 million compared to $242.7 million in Q4 2023 [3][6] - Gross profit margin fell to 59.4%, down 4.8 percentage points from 64.2% in Q4 2023 [3][9] Business Overview - DexCom specializes in continuous glucose monitoring systems, focusing on diabetes management with products like the G6 and G7 systems [4] - The company is investing in product development, including AI advancements, to enhance its offerings and market reach [4][7] Strategic Developments - The introduction of the G7 system and the Dexcom Stelo aims to target non-insulin-using diabetes patients, expanding the product line [5][7] - Significant international revenue growth of 17% was noted, with a 19% organic growth increase, indicating successful market expansion [6][8] - A strategic partnership with ŌURA was announced to integrate glucose data into a broader health management ecosystem [8] Future Outlook - Management anticipates a revenue growth of 14% for fiscal year 2025, with a Non-GAAP operating margin target of around 21% [10] - The approval and expected release of the G7 15-day system in the U.S. is seen as a key milestone for future performance [10]

Core Insights - DexCom reported $1.11 billion in revenue for Q4 2024, a year-over-year increase of 7.6% [1] - The EPS for the same period was $0.45, down from $0.50 a year ago, indicating a -10.00% surprise compared to the consensus estimate [1] - The revenue met the Zacks Consensus Estimate, showing a slight surprise of +0.05% [1] Revenue Breakdown - International revenue was $310.70 million, exceeding the six-analyst average estimate of $307.38 million, with a year-over-year change of +17.1% [4] - U.S. revenue reached $802.80 million, slightly above the $798.41 million average estimate, reflecting a +4.4% year-over-year change [4] - Hardware revenue was $45 million, below the two-analyst average estimate of $46.55 million, showing a significant year-over-year decline of -48.6% [4] - Revenue from sensors and other products was $1.07 billion, slightly above the $1.06 billion estimate, with a year-over-year increase of +12.8% [4] Stock Performance - DexCom shares returned +4.3% over the past month, outperforming the Zacks S&P 500 composite's +3.9% change [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

Core Viewpoint - DexCom reported quarterly earnings of $0.45 per share, missing the Zacks Consensus Estimate of $0.50 per share, representing a -10% earnings surprise [1] - The company posted revenues of $1.11 billion for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 0.05% and showing a year-over-year increase from $1.03 billion [2] Company Performance - Over the last four quarters, DexCom has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times [2] - The stock has gained approximately 7.8% since the beginning of the year, outperforming the S&P 500's gain of 2.9% [3] Future Outlook - The company's earnings outlook is crucial for assessing future stock performance, with current consensus EPS estimates at $0.37 for the coming quarter and $2 for the current fiscal year [7] - The Zacks Rank for DexCom is currently 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Medical - Instruments industry, to which DexCom belongs, is currently in the top 34% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - Another company in the same industry, Globus Medical, is expected to report quarterly earnings of $0.76 per share, reflecting a year-over-year change of +26.7% [9]

Dexcom Dexcom earnings Q4 2024 Digbetes Nasdag Safe harbor statement This presentation also contains non-GAAP financial measures. The appendix reconclies the non-GAAP financial measures in this presentation to the most directly comparable financial measures prepared in accordance with Generally Accepted Accounting Principles (GAAP). These non-G-AP financial mecsures include organic revenue, nor-GAAP gross profit, non-GAAP operating income (loss), non-GAAP operating income (loss), non-GAAP operating margin, ...

Financial Results and Guidance - DexCom will report preliminary, unaudited financial results for Q4 2024 and fiscal year 2024, along with initial financial outlook for fiscal year 2025[3] - The preliminary unaudited financial results for Q4 and fiscal year 2024 are subject to finalization in DexCom's Annual Report on Form 10-K[9] - DexCom's forward-looking statements include preliminary unaudited revenue for Q4 and full fiscal year 2024, including growth rates[9] - DexCom provided total revenue guidance for fiscal year 2025[9] - DexCom provided Non-GAAP Gross Profit Margin and Non-GAAP Operating Margin guidance for fiscal years 2024 and 2025, including expected growth rates[9] Forward-Looking Statements and Risks - DexCom's forward-looking statements also include potential strategic and business opportunities[9] - The forward-looking statements are subject to risks and uncertainties, and actual results may differ materially from current expectations[9] - DexCom assumes no obligation to update forward-looking statements after the date of the report unless required by law[9] Regulatory and Filing Information - The information in Item 2.02 and Exhibit 99.1 is not deemed "filed" under Section 18 of the Securities Exchange Act of 1934[10] - The information in the report and exhibit is not incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act unless expressly set forth[10]

DexCom, Inc. (DXCM) is scheduled to release fourth-quarter 2024 results on Feb. 13, after the closing bell. In the last reported quarter, the company’s earnings beat estimates by 4.65%.The bottom line also outpaced the consensus mark in each of the trailing four quarters, delivering an average surprise of 12.43%.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.Shares of DXCM have gained 23.4% in the past six months compared with the industry’s 4.7% growth. The S&P 500 Index has ralli ...

In its upcoming report, DexCom (DXCM) is predicted by Wall Street analysts to post quarterly earnings of $0.50 per share, reflecting no change compared to the same period last year. Revenues are forecasted to be $1.1 billion, representing a year-over-year increase of 6.5%.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.Prior to a company's ear ...